NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Executive Summary

• NeuroThera Labs Inc. announced the publication of an international PCT patent application covering a novel MEAI‑PEA combination therapy for obesity and metabolic dysfunction‑associated steatotic liver disease (MASLD).
• The collaboration with Clearmind Medicine leverages Clearmind’s 5‑methoxy‑2‑aminoindane (MEAI) platform together with NeuroThera’s palmitoylethanolamide (PEA) to create a non‑hallucinogenic neuroplastogen treatment.
• Management highlights the large global addressable market—~890 million adults with obesity and ~30 % of adults affected by MASLD—and positions the therapy as a potentially safer, easier and more cost‑effective alternative to GLP‑1 agonists.

Key Details

• Patent Publication: International patent application filed under the Patent Cooperation Treaty (PCT) for the MEAI‑PEA combination therapy.
• Therapeutic Targets: Obesity and MASLD (formerly fatty liver disease).
• Mechanistic Claim: Non‑hallucinogenic neuroplastogen that may provide safety and tolerability advantages over existing GLP‑1 agonists.
• Collaboration Structure: Clearmind supplies the MEAI platform; NeuroThera contributes PEA formulation.
• Market Context: Global weight‑loss drug market valued at ~US$37 billion in 2025, projected to reach US$226 billion by 2035.
• Potential Benefits: Safer profile, easier administration, lower cost relative to GLP‑1 agonists.
• Forward‑Looking Statements: Include expectations regarding therapeutic benefits, market demand, regulatory approvals, and ability to raise additional capital.

Notable Quotes

(No direct quotes were provided in the release.)